Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted)NEW YORK, ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.

Germany’s Formycon has decided today to prematurely terminate the Phase III trial (Lotus) for its biosimilar candidate FYB206 ...

Israel-based clinical-stage company Purple Biotech today announced it is advancing into a Phase II study with NT219 in ...

In the fourth quarter of 2024, BB Biotech shares posted a total return of -2.7% in CHF and -3.5% in EUR. NAV performance improved, rising by 2.7% in CHF and 2.8% in EUR, though it declined by 4.3% in ...

Q4 2024 Earnings Call Transcript February 14, 2025 Moderna, Inc. misses on earnings expectations. Reported EPS is $-2.91 EPS, ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

Its Keytruda drug for cancer treatment is performing ... The company’s strong commercial execution, diversified portfolio, and innovative pipeline lend it resilience against short-term headwinds ...

Toyota Motor Corporation (NYSE:TM) is the world’s largest auto manufacturer in terms of sales volume, design, production, assembly, and distribution of cars, minivans, commercial vehicles ...